Back to results
US 2020/0270342 A1Published application
HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
AssigneeAerpio Pharmaceuticals, Inc.
InventorsKevin PETERS, Michael Allen FLYNN
Life of this patent
Estimating the term…
Abstract
The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
Claims19
1-114. (canceled)
An antibody comprising:
- a light chain variable domain sequence that is any one of SEQ ID NOs:
- 20-23, wherein the light chain variable domain sequence comprises complementarity-determining region (CDR) sequences that are SEQ ID NO:
- 57, SEQ ID NO:
- 58, and SEQ ID NO:
- 59, wherein the light chain variable domain sequence is contained within a light chain sequence that is any one of SEQ ID NOs:
- 34-37.
3 more elements
A pharmaceutical composition comprising a therapeutically effective amount of an antibody comprising:
- a light chain variable domain sequence that is any one of SEQ ID NOs:
- 20-23, wherein the light chain variable domain sequence comprises complementarity-determining region (CDR) sequences that are SEQ ID NO:
- 57, SEQ ID NO:
- 58, and SEQ ID NO:
- 59, wherein the light chain variable domain sequence is contained within a light chain sequence that is any one of SEQ ID NOs:
- 34-37;
- and
- a pharmaceutically acceptable carrier.
5 more elements
Dependencies are inferred from the claim text.